OBJECTIVE: To evaluate the performance of QuantiFERON-TB GOLD (QFTG) in a resource-poor setting among patients with and without HIV infection. DESIGN: Cross-sectional study. SETTING: Two hospitals in Northern Tanzania. SUBJECTS: Eighty three adult male and female inpatients. INTERVENTION: All patients were screened for HIV infection and underwent tuberculin skin test (TST) and QFTG. RESULTS: Eighty-three subjects were enrolled, and 29 (35%) of 83 were HIV-infected. QFTG yielded indeterminate results in 12 (22%; 95% CI 12%-34%) of 54 HIV-uninfected and 13 (45%; 95% CI 26%-64%) of 29 HIV-infected subjects (p = 0.0323). Among those with smear-positive pulmonary tuberculosis, TST was positive in 40 (100%; 95% CI 91%-100%) of 40 HIV-uninfected subjects compared with seven (54%; 95% CI 25%-81%) of 13 HIV-infected subjects (p < 0.0001), and QFTG was positive in 28 (70%; 95% CI 53%-83%) of 40 HIV-uninfected subjects compared with three (23%; 95% CI 5%-54%) of 13 HIV-infected subjects (p = 0.0029). Among medical inpatients at risk for latent tuberculosis infection, TST was positive in seven (50%) of 14 HIV-uninfected patients and three (19%) of 16 HIV-infected patients (p = 0.0701) and QFTG was positive among two (14%) of 14 HIV-uninfected patients and three (19%) of 16 HIV-infected patients (p = 0.7437). CONCLUSIONS: The presence of HIV co-infection was associated with a significant reduction in sensitivity of both the TST (p < 0.0001) and QFTG (p = 0.0029) for the diagnosis of active M. tuberculosis infection. The high proportion of indeterminate QFTG and lack of sensitivity, particularly among HIV-infected patients, may limit its applicability in settings like Tanzania. Larger studies in resource-poor settings are required.
OBJECTIVE: To evaluate the performance of QuantiFERON-TB GOLD (QFTG) in a resource-poor setting among patients with and without HIV infection. DESIGN: Cross-sectional study. SETTING: Two hospitals in Northern Tanzania. SUBJECTS: Eighty three adult male and female inpatients. INTERVENTION: All patients were screened for HIV infection and underwent tuberculin skin test (TST) and QFTG. RESULTS: Eighty-three subjects were enrolled, and 29 (35%) of 83 were HIV-infected. QFTG yielded indeterminate results in 12 (22%; 95% CI 12%-34%) of 54 HIV-uninfected and 13 (45%; 95% CI 26%-64%) of 29 HIV-infected subjects (p = 0.0323). Among those with smear-positive pulmonary tuberculosis, TST was positive in 40 (100%; 95% CI 91%-100%) of 40 HIV-uninfected subjects compared with seven (54%; 95% CI 25%-81%) of 13 HIV-infected subjects (p < 0.0001), and QFTG was positive in 28 (70%; 95% CI 53%-83%) of 40 HIV-uninfected subjects compared with three (23%; 95% CI 5%-54%) of 13 HIV-infected subjects (p = 0.0029). Among medical inpatients at risk for latent tuberculosis infection, TST was positive in seven (50%) of 14 HIV-uninfected patients and three (19%) of 16 HIV-infected patients (p = 0.0701) and QFTG was positive among two (14%) of 14 HIV-uninfected patients and three (19%) of 16 HIV-infected patients (p = 0.7437). CONCLUSIONS: The presence of HIV co-infection was associated with a significant reduction in sensitivity of both the TST (p < 0.0001) and QFTG (p = 0.0029) for the diagnosis of active M. tuberculosis infection. The high proportion of indeterminate QFTG and lack of sensitivity, particularly among HIV-infected patients, may limit its applicability in settings like Tanzania. Larger studies in resource-poor settings are required.
Authors: Annie F Luetkemeyer; Edwin D Charlebois; Laura L Flores; David R Bangsberg; Steven G Deeks; Jeffrey N Martin; Diane V Havlir Journal: Am J Respir Crit Care Med Date: 2007-01-11 Impact factor: 21.405
Authors: Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland Journal: Lancet Date: 2006-11-04 Impact factor: 79.321
Authors: A Lalvani; A A Pathan; H McShane; R J Wilkinson; M Latif; C P Conlon; G Pasvol; A V Hill Journal: Am J Respir Crit Care Med Date: 2001-03 Impact factor: 21.405
Authors: N Markowitz; N I Hansen; T C Wilcosky; P C Hopewell; J Glassroth; P A Kvale; B T Mangura; D Osmond; J M Wallace; M J Rosen; L B Reichman Journal: Ann Intern Med Date: 1993-08-01 Impact factor: 25.391
Authors: Molebogeng Xheeda Rangaka; Katalin A Wilkinson; Ronnett Seldon; Gilles Van Cutsem; Graeme Ayton Meintjes; Chelsea Morroni; Priscilla Mouton; Lavanya Diwakar; Tom G Connell; Gary Maartens; Robert J Wilkinson Journal: Am J Respir Crit Care Med Date: 2006-12-07 Impact factor: 21.405
Authors: Catherine M Stein; Sarah Zalwango; LaShaunda L Malone; Bonnie Thiel; Ezekiel Mupere; Mary Nsereko; Brenda Okware; Hussein Kisingo; Christina L Lancioni; Charles M Bark; Christopher C Whalen; Moses L Joloba; W Henry Boom; Harriet Mayanja-Kizza Journal: Am J Epidemiol Date: 2018-07-01 Impact factor: 4.897
Authors: M X Rangaka; H P Gideon; K A Wilkinson; M Pai; J Mwansa-Kambafwile; G Maartens; J R Glynn; A Boulle; K Fielding; R Goliath; R Titus; S Mathee; R J Wilkinson Journal: Eur Respir J Date: 2011-06-30 Impact factor: 16.671
Authors: Irene A Biraro; Moses Egesa; Frederic Toulza; Jonathan Levin; Stephen Cose; Moses Joloba; Steven Smith; Hazel M Dockrell; Achilles Katamba; Alison M Elliott Journal: PLoS One Date: 2014-11-05 Impact factor: 3.240
Authors: Rafal S Sobota; Catherine M Stein; Nuri Kodaman; Isaac Maro; Wendy Wieland-Alter; Robert P Igo; Albert Magohe; LaShaunda L Malone; Keith Chervenak; Noemi B Hall; Mecky Matee; Harriet Mayanja-Kizza; Moses Joloba; Jason H Moore; William K Scott; Timothy Lahey; W Henry Boom; C Fordham von Reyn; Scott M Williams; Giorgio Sirugo Journal: PLoS Genet Date: 2017-06-19 Impact factor: 5.917